Biomarkers to predict the antidepressant response
Research report (imported) 2020 - Max Planck Institute of Psychiatry
The World Health Organization estimates that around 300 million people worldwide are affected by depression. Affective disorders represent one of the most significant causes for the loss of healthy life years and result in a reduced life expectancy compared to the general population. Psychotropic drugs approved for the treatment of depression do not result in disease improvement or even remission in all affected patients. The identification of specific biomarkers that provide each patient with the optimal drug would be an important milestone in personalized psychiatric medicine.